All Blogs

Aug 13, 2020

ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory Pharmaceutical companies and their key presentations. GlaxoSmithKline's Trelegy Ellipta for the treatment of Inadequately Controlled Asthma GlaxoSmithKline is worth mentioning here, as it is presenting key ...

Aug 13, 2020

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...

Aug 12, 2020

Infectious diseases or communicable diseases are one of the leading causes of death worldwide. These diseases are spread by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi. Infectious diseases possess greater risk as these diseases can easily transfer from human to human or by other modes....

Aug 11, 2020

Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy  The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche company, for spinal muscular atrophy (SMA), an inherited neuromuscular disease resulting in muscle atrophy, in adults and...

Aug 10, 2020

Merck’s Gefapixant could become the first drug approved for Chronic Cough ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations. Merck is worth mentioning here, as it is presenting key posters and...

Aug 10, 2020

ATS 2020 Virtual is scheduled to be held from August 5 to August 10, and it is exciting to watch the key presentations by Pharmaceutical Companies specifically focused on pulmonary disease, critical illness, and sleep disorders. Boehringer Ingelheim presented new analyses of Ofev data in patients with chronic fi...

Aug 10, 2020

The influx of companies, the launch of pipeline therapies, and the legalization of marijuana/ cannabis are the major drivers of the medical marijuana market. Cannabis, popularly known as Marijuana, is the most commonly used illicit drug after alcohol. More than 150 Million people regularly smoke marijuana. Appr...

Aug 06, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company informed that the DNA vaccine was well tolerated in the first stage of t...

Aug 07, 2020

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies.Among the 7MM geographies, the US accounted for the 54% share of the total hATTR m...

Aug 05, 2020

The Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder that affects children and teens. ADHD is mostly recognised during the early school years and can also continue into adulthood. ADHD includes symptoms such as inattentiveness, hyperactivity, and impulsiveness. Often referred...